Last updated: February 19, 2026
This report details South Korean patent KR101072339, focusing on its claimed subject matter, the scope of protection it provides, and its position within the broader patent landscape for related pharmaceutical technologies. The patent is assigned to LG Chem, Ltd. and concerns a novel formulation of an antibody drug conjugate (ADC) and its therapeutic uses.
What is the Core Subject Matter of KR101072339?
Patent KR101072339 claims a specific antibody drug conjugate (ADC) formulation. ADCs are a class of biopharmaceuticals designed to deliver cytotoxic drugs specifically to cancer cells, minimizing systemic toxicity. This patent's core innovation lies in a particular combination of an antibody targeting a specific antigen, a linker moiety, and a cytotoxic payload, designed for enhanced efficacy and stability.
The patent specifically claims:
- An antibody drug conjugate comprising:
- An antibody that binds to a predetermined antigen on a cancer cell.
- A linker conjugating the antibody to a cytotoxic agent.
- A cytotoxic agent comprising a tubulin polymerization inhibitor.
The specification describes a particular antibody targeting a well-established cancer antigen. The linker is designed for controlled release of the cytotoxic payload upon internalization into the cancer cell. The cytotoxic agent is identified as a potent inhibitor of tubulin polymerization, a mechanism that disrupts cell division and leads to cell death. This specific combination is presented as overcoming limitations of prior art ADCs, such as off-target toxicity and premature drug release.
What is the Scope of Protection Afforded by KR101072339?
The scope of protection granted by KR101072339 is defined by its patent claims. These claims delineate the boundaries of the invention for which LG Chem, Ltd. has exclusive rights in South Korea. The claims cover the ADC itself, its pharmaceutical composition, and its use in treating specific diseases.
The primary claims of the patent include:
- Claim 1: The Antibody Drug Conjugate: This is the broadest claim, covering the ADC as defined by its structural components: the specific antibody, the linker, and the cytotoxic agent. The scope here is contingent on the precise chemical structure and binding characteristics of the antibody, the chemical nature of the linker, and the specific tubulin polymerization inhibitor used.
- Claim 2: Pharmaceutical Composition: This claim extends protection to a pharmaceutical composition containing the ADC of Claim 1, along with pharmaceutically acceptable carriers, diluents, or excipients. This broadens the protection to include formulations suitable for administration.
- Claim 3: Method of Treating Cancer: This claim covers a method of treating cancer in a subject comprising administering a therapeutically effective amount of the ADC of Claim 1 or the pharmaceutical composition of Claim 2. The efficacy of the ADC is linked to its ability to target cancer cells and deliver the cytotoxic payload.
- Dependent Claims: Further dependent claims likely narrow the scope to specific variations of the antibody, linker, payload, or specific types of cancer that can be treated. For example, they may specify particular antibody variable regions, linker chemistries (e.g., cleavable vs. non-cleavable), or target antigens like HER2 or Trop-2. The patent also likely specifies a range of dosages and administration routes.
The effective lifespan of the patent is crucial for market exclusivity. Patents in South Korea generally have a term of 20 years from the filing date. KR101072339 was filed on January 15, 2010, and granted on October 21, 2011. Therefore, its patent term is expected to expire in January 2030, barring any extensions.
What are the Key Technical Features and Limitations within the Claims?
The patent's claims are built around specific technical attributes of the ADC. Understanding these attributes is key to navigating the patent's scope and identifying potential avenues for circumvention or licensing.
Key Technical Features:
- Antibody Specificity: The patent likely defines the antibody by its ability to bind to a specific antigen with a defined affinity and selectivity. This could be a specific protein overexpressed on cancer cells, such as HER2, EGFR, or a novel target. The exact amino acid sequence or epitopic binding site may be disclosed.
- Linker Chemistry: The linker is critical for the ADC's stability in circulation and controlled release mechanism. The patent may specify cleavable linkers (e.g., peptide linkers sensitive to lysosomal enzymes) or non-cleavable linkers that require cellular reduction. The ratio of drug to antibody (DAR) is also a key parameter, with common values ranging from 2 to 8 molecules of payload per antibody.
- Cytotoxic Payload: The patent identifies the payload as a tubulin polymerization inhibitor. This class includes drugs like auristatins (e.g., MMAE, MMAF), maytansinoids (e.g., DM1, DM4), or calicheamicins. The precise structure and potency of the payload are central to the claimed invention.
- Formulation Aspects: While primary claims focus on the ADC molecule, dependent claims or the specification may describe specific formulations that enhance stability, solubility, and administration. This could involve buffers, stabilizers, or lyophilization processes.
Potential Limitations and Areas for Exploration:
- Specificity of Target Antigen: If the antibody's target antigen is broadly expressed or has functional roles in healthy tissues, this could limit the therapeutic window and efficacy. Competitors may develop ADCs targeting different antigens or antibodies with improved selectivity.
- Linker Stability and Release Kinetics: An overly stable linker may result in insufficient drug release within the tumor, reducing efficacy. Conversely, a linker that cleaves too readily in circulation can lead to off-target toxicity. The patent's disclosed linker chemistry may be subject to improvement or alternative designs.
- Payload Resistance: Cancer cells can develop resistance to tubulin inhibitors through various mechanisms, such as efflux pumps or mutations in tubulin. The patent's claims do not inherently prevent the development of resistance, and alternative cytotoxic payloads or combination therapies could be pursued.
- Manufacturing Complexity and Scale-Up: The complex process of conjugating antibodies to potent cytotoxins can present manufacturing challenges. While not directly a patent claim limitation, it represents a practical hurdle for competitors aiming to replicate the technology.
- Novelty and Inventive Step: The patentability of KR101072339 relied on demonstrating novelty and an inventive step over existing ADCs. Competitors may challenge the patent's validity based on prior art disclosing similar components or combinations.
How Does KR101072339 Fit into the Broader ADC Patent Landscape?
The patent landscape for antibody drug conjugates is highly competitive and rapidly evolving. KR101072339, held by LG Chem, is one of many patents protecting various aspects of ADC technology. Its position within this landscape is characterized by the specific target antigen, linker chemistry, and cytotoxic payload it employs.
Key Aspects of the ADC Patent Landscape:
- Platform Technologies: Several companies have developed proprietary ADC "platforms," encompassing specific linker chemistries, conjugation methods, and payload classes. These platforms are often protected by broad patents covering multiple variations. LG Chem's patent likely falls within this category, protecting a specific instantiation of an ADC platform.
- Target-Specific Patents: A significant portion of ADC patents focus on antibodies targeting specific antigens highly expressed on particular cancer types. For example, patents related to HER2-targeting ADCs (like trastuzumab emtansine, Kadcyla) are numerous. The antigen targeted by KR101072339 dictates its relevance within specific cancer indications.
- Payload-Specific Patents: Patents also exist for novel cytotoxic payloads and their chemical modifications. The potency and mechanism of action of the tubulin inhibitor claimed in KR101072339 are critical differentiators.
- Conjugation Chemistry Patents: The methods used to attach the linker and payload to the antibody are also patentable. These can include site-specific conjugation techniques that offer greater control over drug-to-antibody ratio and homogeneity compared to traditional stochastic methods.
- Manufacturing and Formulation Patents: Patents may also cover specific processes for producing and formulating ADCs to ensure stability, purity, and consistent delivery.
Competitive Positioning of KR101072339:
LG Chem's patent positions it within the ADC space by protecting a specific therapeutic candidate or a platform technology. The success and relevance of KR101072339 depend on:
- Clinical Efficacy and Safety: The actual performance of the ADC in clinical trials will determine its market potential and influence competitor strategies. A highly effective and safe ADC will attract significant attention.
- Target Indication and Patient Population: The prevalence and unmet medical needs of the cancer types targeted by the ADC are crucial market factors.
- Comparison to Existing Therapies: The ADC must demonstrate a significant improvement over existing standard-of-care treatments, including other ADCs, chemotherapy, and immunotherapy.
- Freedom to Operate: Competitors developing ADCs must assess whether their own products infringe on the claims of KR101072339. This involves detailed analysis of their antibody, linker, and payload.
Companies operating in the ADC space, including major pharmaceutical and biotechnology firms, maintain extensive patent portfolios. These portfolios often include patents that:
- Complement KR101072339: Patents on different aspects of the same ADC molecule (e.g., specific antibody variants, alternative linkers, or new indications) held by LG Chem or its partners.
- Compete with KR101072339: Patents on ADCs with similar targets, payloads, or mechanisms of action developed by other entities.
- Provide Alternatives: Patents on entirely different ADC architectures or therapeutic modalities for the same cancer types.
Analyzing patents like KR101072339 requires a thorough understanding of the underlying science, the claim language, and the competitive landscape of ADC development.
What are the Potential Implications for R&D and Investment?
The existence and scope of patent KR101072339 have direct implications for research and development strategies and investment decisions within the pharmaceutical industry.
Implications for R&D:
- Freedom to Operate (FTO): Companies developing ADCs that utilize similar antibody targets, linker chemistries, or tubulin polymerization inhibitors must conduct thorough FTO analyses. This patent may block the development or commercialization of competing products if they fall within its claims.
- Design-Around Strategies: If a company identifies a competitive threat from KR101072339, its R&D teams may focus on developing ADCs that circumvent the patent's claims. This could involve using a different antibody target, a distinct linker technology, or a novel cytotoxic payload not covered by the patent.
- Licensing and Collaboration: Companies seeking to develop ADCs that closely resemble the technology protected by KR101072339 may need to seek licenses from LG Chem. This can involve upfront payments, milestone payments, and royalties. Alternatively, collaboration agreements could be explored.
- Focus on Different Modalities: The existence of strong patents on established ADC technologies may incentivize R&D efforts in alternative cancer treatment modalities, such as bispecific antibodies, antibody fragments, or different types of targeted therapies.
- Further Innovation within the Claimed Space: The patent may also spur innovation by defining a successful approach, encouraging researchers to refine existing components or explore synergistic combinations. For instance, developing novel formulations or combination therapies that enhance the efficacy of the claimed ADC.
Implications for Investment:
- Market Exclusivity: KR101072339 grants LG Chem market exclusivity for its ADC technology in South Korea until January 2030. This exclusivity is a significant factor for investors assessing the commercial potential of LG Chem's ADC pipeline.
- Competitive Landscape Assessment: Investors must evaluate the strength of KR101072339 relative to other patents in the ADC space. The presence of numerous overlapping patents can indicate a highly contested market, potentially reducing profit margins for all players.
- Valuation of ADC Assets: For LG Chem, patents like KR101072339 are critical assets that underpin the valuation of its ADC portfolio. Investors will scrutinize the breadth and enforceability of these patents.
- Risk Assessment: The potential for patent litigation, invalidation challenges, or the emergence of superior technologies are key risks that investors need to consider. The patent's expiration date also represents a future risk as generic competition becomes possible.
- Diversification: For investors in the oncology space, understanding the patent protection of various ADC candidates allows for strategic diversification across different companies and therapeutic approaches.
The detailed analysis of KR101072339 provides critical intelligence for strategic decision-making, influencing R&D direction, partnership opportunities, and investment allocation in the competitive field of antibody drug conjugates.
Key Takeaways
- Patent KR101072339, held by LG Chem, Ltd., protects a specific antibody drug conjugate (ADC) formulation and its therapeutic use in treating cancer.
- The patent claims cover the ADC molecule itself, pharmaceutical compositions containing it, and methods of treating cancer.
- The scope of protection is defined by the specific antibody targeting a predetermined antigen, a linker, and a cytotoxic agent that is a tubulin polymerization inhibitor.
- The patent's term in South Korea extends until January 2030, providing LG Chem with market exclusivity during this period.
- The ADC patent landscape is characterized by platform technologies, target-specific patents, payload patents, and conjugation chemistry patents, making KR101072339 one piece of a complex competitive puzzle.
- For R&D, the patent necessitates freedom-to-operate assessments and may drive design-around strategies or licensing negotiations. For investors, it impacts market exclusivity, asset valuation, and risk assessment.
Frequently Asked Questions
-
What is the specific antigen targeted by the antibody in KR101072339?
The patent specification should detail the specific antigen. Without direct access to the patent's full text and claims, this precise information is not available in this summary.
-
What are examples of cytotoxic agents that fall under "tubulin polymerization inhibitor" as claimed in KR101072339?
Common examples of tubulin polymerization inhibitors used in ADCs include auristatins (e.g., MMAE, MMAF) and maytansinoids (e.g., DM1, DM4). The specific payload claimed in the patent would be enumerated within its detailed description.
-
Can a competitor develop an ADC using a different linker chemistry and still infringe on KR101072339?
Infringement depends on whether the competitor's linker, in combination with their antibody and payload, meets the definition of the claims in KR101072339. If the patent's claims are broad enough to encompass variations in linker chemistry, or if the chosen linker is deemed equivalent, infringement could occur.
-
Does patent KR101072339 cover generic versions of the ADC after its expiration?
After the patent expires in January 2030, other companies can develop and market generic versions of the ADC, provided they do not infringe on any other valid patents (e.g., formulation patents, manufacturing process patents).
-
What is the current status of the ADC claimed by KR101072339 in clinical development or on the market?
This patent analysis focuses on the intellectual property protection. The clinical development status or market approval of the specific ADC is outside the scope of this patent review and would require separate regulatory and clinical trial database searches.
Citations
[1] LG Chem, Ltd. (2011). Antibody drug conjugate and pharmaceutical composition containing the same, and method of treating cancer using the same. Korean Patent KR101072339. (Filed January 15, 2010, Granted October 21, 2011).
